| Date | Title | Description |
| 24.04.2025 | Commit Biologics announces €5.5m seed financing extension investment by Korys to further develop its Bispecific Complement Engaging (BiCE™) platform | Aarhus, Denmark, 28 January 2025, Commit Biologics (“Commit”), a pioneer in the activation of the complement system to treat cancer and autoimmune disease, today announces a €5.5m extension to its seed financing. The contribution from new i... |
| 02.02.2025 | Commit Biologics Secures €5.5M to Revolutionize Cancer Treatment | In the heart of Aarhus, Denmark, a biotech company is on a mission. Commit Biologics has raised €5.5 million in an extension of its seed financing. This funding, bolstered by new investor Korys, brings the total seed funding to €21.5 millio... |
| 01.02.2025 | Commit Biologics: €5.5 Million (Seed) Raised To Develop Cancer Treatments | Commit Biologics – an innovator in activating the complement system to treat cancer and autoimmune disease – announced a €5.5 million extension to its seed funding. The contribution from new investor Korys brings the total seed funding rais... |
| 28.01.2025 | Commit Biologics Raises €5.5M in Seed Financing Extension | Commit Biologics, an Aarhus, Denmark-based company which specializes in the activation of the complement system to treat cancer and autoimmune disease, raised €5.5M in Seed extension funding.
The round included the contribution from new inv... |
| 15.01.2025 | Commit Biologics appoints accomplished R&D executive, Dr Janine Schuurman, to its Board of Directors | Aarhus, Denmark, 8 January 2025 – Commit Biologics (“Commit”), a pioneer in the activation of the complement system to treat cancer and autoimmune disease, today announces the appointment of Janine Schuurman, Ph.D. to its Board of Directors... |
| 22.12.2024 | Commit Biologics appoints Mikkel Wandahl Pedersen as Chief Scientific Officer | Aarhus, Denmark, 15 October 2024 – Commit Biologics (“Commit”), a pioneer in the activation of the complement system to treat cancer and autoimmune disease, today announces the appointment of Mikkel Wandahl Pedersen as Chief Scientific Offi... |
| 07.09.2024 | Commit Biologics launches with €16m seed financing to pioneer complement system activation to treat cancer and autoimmune disease | Aarhus, Denmark – 9 May 2024 – Commit Biologics (“Commit”), a pioneer in the activation of the complement system to treat cancer and autoimmune disease, today exits from stealth with €16m in seed funding from Bioqube Ventures and Novo Holdi... |
| 12.08.2024 | The endgame: 10 European startups aiming to defeat cancer | Cancer remains one of the most pressing global health challenges, claiming millions of lives each year and impacting countless more. Despite significant advancements in research and treatment, the fight against cancer demands continuous inn... |
| 09.05.2024 | Commit Biologics Raises €16M in Seed Financing | Commit Biologics, an Aarhusm, a Denmark-based company which specializes in activating the complement system to treat cancer and autoimmune disease, raised €16M in Seed funding.
Backers included Bioqube Ventures and Novo Holdings.
The compan... |
| - | Commit Biologics | “Add a description about your page or projects. Should be around 135 to 160 characters.” |
